Australia - Telco Company Profiles - 2nd Tier
Rapid consolidation in the 2nd tier market The 2nd tier market Developments in this market have been dominated by industry consolidation, a process that is set to continue over coming years. Moving towards a structurally separated regulatory environment with a NBN at the horizon, size really does matter. To Read the Complete Report with TOC Visit:
The other important development has been Telstraâ€™s aggressive activities to increase its market share, particularly in the mobile and broadband sectors. This has been detrimental to a number of 2nd tier players, as has been reflected in their declining revenue in 2013. Nevertheless, there was an overall recovery in total revenue among these players in 2013, reflecting the benefits of scale brought about by market consolidation. Overal revenue for these operators, of about $3.9 billion, still accounts for less than 10% of the total telecoms market in Australia. The NBN, and in particular the structural separation between infrastructure and services, is going to change the telecoms industry beyond recognition. Gone will be the days of regulatory gaming. A completely new industry structure will require collaboration and cooperation, rather than the destructive adversarial environment of the past. However, before that open market is established, Telstra will still dominate the current market structure, and with its NBN bounty has deep pockets to invest in new opportunities. Another question is whether the design of the NBN will lead to true wholesale competition; or will it restrict this to a handful of players who can afford to build their presence in the 121 points of interconnect? This could well prove to be a critical strategic mistake. The ACCC who approved this has already indicated that this will be one of the main areas it will be monitoring. The unique construction that offers backhaul competition could indeed be the facilitator in obtaining the competitive outcome needed to ensure that a dynamic system is developed which will lead to innovation.
Industry collaboration will also be needed to limit the necessity for more regulation. In a dynamic environment time is money and there is no longer room for year-long regulatory processes. Trust needs to be built up to facilitate much speedier dispute resolution, preferably preventing these disputes from arising in the first place. Some early indications are that NBN Co is willing to sit down and make changes where it makes sense to create a better wholesale and retail environment for all involved. Click Here To Download Detail Report:
Table of Contents 1. Telecoms Market Revenue Overview 1.1 Total telco market by major service 1.2 Wholesale market 1.2.1 The market into 2014 1.2.2 Wholesale revenue 1.3 Mobile market 1.3.1 Market overview and analysis 1.3.2 Revenue by service 1.3.3 Average revenue per user (ARPU) 1.4 Broadband market 1.4.1 Internet access revenues 2. National Broadband Network 2.1 Wholesale and Competition 2.1.1 The NBN (after the elections) and the competition issues 2.1.2 National Broadband Network – Policies and Regulations 2.1.3 Wholesale Product Overview 2.1.4 The NBN wholesale and PoI debate 2.1.5 NBN Co’s multicast service 2.1.6 Pricing Strategies 2.1.7 NBN Utility Management service – The Retail Clause 2.1.8 Do we need infrastructure-based competition? 3. Amcom Telecommunications Limited 3.1 Company information 3.1.1 Overview 3.2 Company analysis 3.2.1 Well defined strategies 3.2.2 Independence from others 3.2.3 National broadband network (NBN)
3.3 Financial results 3.3.1 Year 2013 3.3.2 Year 2012 3.3.3 Year 2011 3.3.4 Financial statistics 3.4 Products and services 3.4.1 Divisional overview 3.4.2 Amnet 3.4.3 Data Networks 3.5 Network 3.5.1 Fibre network overview 3.5.2 SABRENet and maintenance agreement 3.6 Acquisitions, alliances and subsidiary companies 3.6.1 Acquisition overview 3.6.2 Amcom acquires IP Systems (IPS) 3.6.3 Amcom acquires L7 IT group 3.6.4 Partnership with BlueFire cloud services 3.6.5 Subsidiary companies 3.7 Company history 3.7.1 Brief timeline â€“ 1988 - 2013 4. iiNet 4.1 Company information 4.1.1 Overview 4.1.2 Current issues 4.2 Financial results 4.2.1 Year 2013 4.2.2 Year 2012 4.2.3 Year 2011 4.3 Operating results 4.3.1 Subscriber statistics 4.4 Company analysis 4.5 Network 4.5.1 Overview 4.5.2 DSLAM rollout 4.5.3 Dark fibre 4.5.4 Fibre-to-the-Home (FttP) 4.5.5 iiNetâ€™s plans for undersea network expansion taking shape 4.6 Acquisitions, alliances and subsidiary companies 4.6.1 Acquisition overview 4.6.2 Partnership with Polycom 4.6.3 Acquisition of ISP Westnet 4.6.4 Alliance with FOX Sports 4.6.5 Alliance with Hypernia
4.6.6 Alliance with Hybrid Television Services 4.6.7 Alliance with Hutchison 4.6.8 Amcom and PowerTel acquire stake in iiNet 4.6.9 Partnership with FetchTV 4.6.10 Acquisition of AAPT Consumer Division 4.6.11 Acquisition of Supernerd 4.6.12 Acquisition of TransACT 4.6.13 Acquisition of Internode 4.6.14 Acquisition of Adam Internet 4.7 Products and services 4.7.1 Home and SOHO 4.7.2 Business 4.7.3 Reselling agreements 4.8 Company history 4.8.1 Brief timeline â€“ 1993 - 2013 5. Macquarie Telecom 5.1 Company information 5.1.1 Overview 5.2 Financial results 5.2.1 FY 2013 5.2.2 FY 2012 5.2.3 FY 2011 5.2.4 Operating revenues and statistical overview 5.3 Company Analysis 5.3.1 Leader in managed business services 5.3.2 National Broadband Network (NBN) 5.4 Data network 5.4.1 Metro Access Network (MAN) 5.4.2 Mobile network 5.5 Services 5.5.1 Hosting solutions 5.5.2 Telco 5.5.3 Management tools 5.5.4 Data centres 5.5.5 Macquarie Telecom Enterprise Cloud 5.6 Company history 5.6.1 Brief timeline â€“ 1992 - 2013 6. M2 Telecommunications 6.1 Company information 6.1.1 Overview 6.2 Company analysis 6.2.1 Growing the company
6.2.2 Arriving in the top ten 6.3 Financial results 6.3.1 Year 2013 6.3.2 Year 2012 6.3.3 Year 2011 6.3.4 Financial statistics overview 6.4 Services 6.4.1 Fixed-line voice 6.4.2 Mobile 6.4.3 Internet 6.4.4 Brands 6.5 Products and services 6.5.1 Overview 6.5.2 M2 Telecom (retail) 6.5.3 M2 Wholesale 6.6 Acquisitions, alliances and subsidiary companies 6.6.1 Acquisition overview 6.6.2 Acquisition Dodo – 2013 6.6.3 Acquisition Eftel – 2013 6.6.4 Acquisition Primus Telecommunications – 2012 6.6.5 Acquisition Time Group – 2012 6.6.6 Acquisition of Flextalk – 2012 6.6.7 Acquisition of AUSTAR Mobile – 2011 6.6.8 Acquisition of Clear Telecoms (M2 Clear) – 2011 6.6.9 Acquisition of Bell Networks – 2010 6.6.10 Acquisition of Clever Communications – 2010 6.6.11 Acquisition of People telecom – 2009 6.6.12 Acquisition of Commander assets – 2009 6.6.13 Acquisition of Unitel Australia – 2008 6.6.14 Acquisition of Orion Telecom – 2007 6.6.15 Acquisition of Tenex Communications – 2007 6.6.16 Acquisition of Wholesale Communications – 2007 6.7 Company history 6.7.1 Brief timeline – 1999 - 2013 7. Foxtel 7.1 Company information 7.1.1 Overview 7.2 Operational results 7.2.1 2013 7.2.2 2012 7.2.3 2011 7.2.4 Subscriber statistics 7.2.5 Historic subscriber statistics
7.3 Financial results 7.3.1 FY 2013 7.3.2 FY 2012 7.3.3 FY 2011 7.3.4 Statistical financial overview 7.3.5 Historical statistical financial overview 7.4 Acquisitions, alliances and subsidiary companies 7.4.1 Acquisition of AUSTAR 7.4.2 Acquisition of Premium Movie Partnership (Showtime) 7.5 Products and services 7.5.1 Digital pay TV 7.5.2 Apps availability and the move to IPTV 7.5.3 FOXTEL further expanding IPTV availability 7.5.4 Optus resells 1Q HD 7.5.5 Triple-play services 7.5.6 Satellite services 7.5.7 Operating centres in Sydney and Melbourne 7.6 Company history 7.6.1 Brief timeline â€“ 1994 - 2013 To Buy The Copy of This Report Visit:
8. Nextgen Networks Pty Limited 8.1 Company information 8.1.1 Overview 8.1.2 Background information on company ownership 8.1.3 Recent developments 8.2 NBN - Regional Backbone Blackspots Program (RBBP) 8.2.1 Background information 8.3 Network 8.3.1 Overview 8.4 Products and services 8.4.1 Introduction 8.4.2 High-speed internet 8.4.3 Transmission 8.4.4 Data centres 8.4.5 Customised data solutions 8.5 Acquisitions and alliances 8.5.1 Nextgen acquires Silk telecom (Silk) 8.6 Company history 8.6.1 Brief timeline â€“ 2000 - 2013 9. TPG Telecom
9.1 Company information 9.1.1 Overview 9.2 Company analysis 9.3 Latest developments 9.3.1 TPG offers low cost mobile broadband 9.3.2 TPG moves with TrustedCloud 9.3.3 Acquires AAPT 9.3.4 Secures mobile spectrum 9.3.5 Invests in subsea cable 9.4 Company divisional overview 9.4.1 Company structure 9.5 Network Latest Reports: Type 2 Diabetes Therapeutics Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019: http://www.marketresearchreports.biz/analysis-details/type-2-diabetestherapeutics-market-to-2019-a-shifting-treatment-algorithm-and-intensifiedcompetition-expected-to-drive-growth-by-2019
Pharmaceuticals industry, â€œType 2 Diabetes Therapeutics Market to 2019 A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019â€?. There is currently a large number of blood glucoselowering drugs in the crowded type 2 diabetes market indicated for the treatment of chronically high blood glucose. The market is led by Lantus, which achieved global sales amounting to $6.4 billion in 2012. Over the forecast period from 2012 to 2019, the safer, more efficacious newer classes of drug (GLP-1 agonists, DPP-4 Inhibitors and SGLT-2 inhibitors) are expected to capture substantial market shares, largely replacing older classes such as sulfonylureas and thiazolidinediones. Additionally, a variety of novel drugs belonging to these newer classes are due to enter the market, and are expected to offer a moderate improvement in terms of efficacy and safety. The price of these new therapies is expected to be high, but this is unlikely to hinder their uptake. As a result, as well as an overall increase in the prevalent population, GBI Research believes that the value of the global market has the potential to grow to reach $38.8 billion by 2019. Scope
A brief introduction to type 2 diabetes, including the symptoms, pathogenesis, risk factors and diagnosis In-depth analysis of major glucose-lowering drugs for type 2 diabetes, including analyses of their safety, efficacy, treatment patterns, strengths/weaknesses and overall commercial prospects. Includes a heat map comparing major drugs in terms of safety, efficacy and dosing parameters. Comprehensive review of the pipeline for type 2 diabetes therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets. Additional in-depth analysis of pipeline drug clinical trials by phase, molecule type, trial size, trial duration and program failure rate analyses for each molecule type and mechanism of action Multi-scenario forecast data for the market up to 2019, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and changes in disease epidemiology across key developed markets including the US, Japan, Germany, the UK, France, Italy and Spain Discussion of the drivers and barriers for market growth Click Here To Download Detail Report: http://www.marketresearchreports.biz/sample/sample/177234
Reasons to buy Understand the many different types of type 2 diabetes therapies on the market, from the older, established classes of treatment to newer, moderately superior types of drug, and their positions in the treatment algorithm Understand the strengths and weaknesses of each product Understand the scope of the pipeline, including which molecule types and mechanisms of action are prominent Observe trends in clinical trial duration and size amongst clinical phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for type 2 diabetes therapeutics Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the type 2 diabetes therapeutics market. Monoclonal Antibodies Market in Breast Cancer to 2019 - Strong Uptake of Novel HER-2 Targeted Therapies to Drive Robust Growth: http://www.marketresearchreports.biz/analysis-details/monoclonal-antibodies-
Pharmaceutical report â€œMonoclonal Antibodies Market in Breast Cancer to 2019 - Strong Uptake of Novel HER-2 Targeted Therapies to Drive Robust Growthâ€?. The current market for breast cancer consists of five monoclonal Antibodies (mAbs), three of which are targeted at the Human Epidermal growth factor Receptor 2 (HER-2) protein. Four are aimed at improving overall survival in the metastatic setting, and two of these have also received further approvals in the early setting in order to improve long-term remission rates. The market is currently led by the HER-2 inhibitor Herceptin, which achieved global sales amounting to $6.2 billion in 2012. Over the forecast period from 2012 to 2019, the two novel HER-2 inhibitors, Kadcyla and Perjeta, are expected to achieve strong market penetration due to their appreciable incremental efficacy benefits. Additionally, the market conditions are currently favorable towards mAbs, with a low rate of price depreciation following patent expiry and a high rate of inflation for specialty pharmaceuticals in the US. As a result of this, and despite the empty Phase III pipeline, GBI Research believes that the global market across the leading eight countries have the potential to grow to a value of $10.6 billion by 2019. Scope An introduction to the treatments available for breast cancer, treatment algorithms and the contexts in which mAbs are clinically relevant to this type of cancer. In-depth analysis of the five mAbs approved for breast cancer, with analysis of their safety, efficacy, treatment patterns and strengths and weaknesses. This includes a heat map comparing the drugs in terms of clinical trial results. A comprehensive review of the pipeline for breast cancer therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline for mAbs is analyzed on the basis of phase distribution, program type and molecular target, as is the entire pipeline for all molecule types. Detailed analysis of pipeline drug clinical trials by trial size, trial duration and program failure rate for each molecule type and mechanism of action. Additionally, a detailed analysis of clinical trial endpoints is provided, detailing their importance in this disease area and their commercial relevance to currently marketed products.
Multi-scenario forecast data for the market is provided to 2019, which takes into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets including the US, Japan, Germany, the UK, France, Italy and Spain. Discussion of the drivers and barriers for market growth Complete analysis of licensing and co-development deals in this market, by year, value, molecule type, Phase and mechanism of action. Additionally, the international network of licensing deals in breast cancer is mapped out by geography. Click Here To Download Detail Report:
Reasons to Buy Understand the different indications for breast cancer, from early-stage to the metastatic disease Grasp the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent, and the context of mAbs in the pipeline Pinpoint the trends in clinical trial duration and size amongst clinical Phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for breast cancer therapeutics. Determine the risk associated with the development of mAbs compared to other molecule types. Observe the shift in clinical trial endpoints by clinical Phase, and use this data to potentially influence any future developmental programs. Understand the importance of selecting the correct endpoints in the study of drugs for this disease. Assess the potential clinical and commercial impact of recently-approved molecules on the breast cancer market and determine the potential revenues associated with the launch of a novel product, in addition to the level of competitiveness in the market. About Us
MarketResearchReports.Biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
Contact M/s Sheela 90 Sate Street, Suite 700 Albany, NY 12207 Tel: +1-518-618-1030 USA â€“ Canada Toll Free: 866-997-4948 Website: http://www.marketresearchreports.biz/ Blog: http://mrrfocuseconomics.blogspot.com/